ALDEYRA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ALDEYRA THERAPEUTICS, INC. (ALDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.76 per share for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-29.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2018-03-29
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2017 was $3.76, a 30.76% decline from fiscal 2016.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2016 was $5.43, a 30.21% decline from fiscal 2015.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $7.78, a 52.85% increase from fiscal 2014.
- ALDEYRA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2014 was $5.09, a 52.16% decline from fiscal 2013.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|
| 2017-12-31 | $3.76 10-K · filed 2018-03-29 | |
| 2016-12-31 | $5.43 10-K · filed 2018-03-29 | |
| 2015-12-31 | $7.78 10-K · filed 2017-03-30 | $5.75 10-K · filed 2016-03-30 |
| 2014-12-31 | $5.09 10-K · filed 2016-03-30 | $6.84 10-K · filed 2015-03-23 |
| 2013-12-31 | $10.64 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |